Browse by Journal Title

2024

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernández-Sánchez, A., González, T., Sobas, M., Sträng, E., Castellani, G., Abáigar, M., Valk, P.J.M., Villaverde Ramiro, Á., Benner, A., Metzeler, K.H., Azibeiro, R., Tettero, J.M., Martínez-López, J., Pratcorona, M., Martínez Elicegui, J., Mills, K.I., Thiede, C., Sanz, G., Döhner, K., Heuser, M., Haferlach, T., Turki, A.T., Reinhardt, D., Schulze-Rath, R., Barbus, M., Hernández-Rivas, J.M., Huntly, B., Ossenkoppele, G., Döhner, H. and Bullinger, L.
Leukemia 38 (9): 1929-1937. September 2024

In vivo CRISPR/Cas9-mediated screen reveals a critical function of TFDP1 and E2F4 transcription factors in hematopoiesis.
Tran, N.T., Graf, R., Acevedo-Ochoa, E., Trombke, J., Weber, T., Sommermann, T., Salomon, C., Kühn, R., Rajewsky, K. and Chu, V.T.
Leukemia 38 (9): 2003-2015. September 2024

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Derigs, P., Schubert, M.L., Dreger, P., Schmitt, A., Yousefian, S., Haas, S., Röthemeier, C., Neuber, B., Hückelhoven-Krauss, A., Brüggemann, M., Bernhard, H., Kobbe, G., Lindemann, A., Rummel, M., Michels, B., Korell, F., Ho, A.D., Müller-Tidow, C. and Schmitt, M.
Leukemia 27 August 2024 (In Press)

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends, C.M., Kopp, K., Hablesreiter, R., Estrada, N., Christen, F., Moll, U.M., Zeillinger, R., Schmitt, W.D., Sehouli, J., Kulbe, H., Fleischmann, M., Ray-Coquard, I., Zeimet, A., Raspagliesi, F., Zamagni, C., Vergote, I., Lorusso, D., Concin, N., Bullinger, L., Braicu, E.I. and Damm, F.
Leukemia 38 (6): 1378-1389. June 2024

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs, M., Jacob, A.S., Kaul, H., Kobe, C., Kuhnert, G., Pabst, T., Greil, R., Bröckelmann, P.J., Topp, M.S., Just, M., Hertenstein, B., Soekler, M., Vogelhuber, M., Zijlstra, J.M., Keller, U.B., Krause, S.W., Dührsen, U., Meissner, J., Viardot, A., Eich, H.T., Baues, C., Diehl, V., Rosenwald, A., Buehnen, I., von Tresckow, B., Dietlein, M., Borchmann, P., Engert, A. and Eichenauer, D.A.
Leukemia 38 (1): 160-167. January 2024

2023

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
Briest, F., Noerenberg, D., Hennch, C., Yoshida, K., Hablesreiter, R., Nimo, J., Sasca, D., Kirchner, M., Mansouri, L., Inoue, Y., Wiegand, L., Staiger, A.M., Casadei, B., Korkolopoulou, P., Weiner, J., Lopez-Guillermo, A., Warth, A., Schneider, T., Nagy, Á., Klapper, W., Hummel, M., Kanellis, G., Anagnostopoulos, I., Mertins, P., Bullinger, L., Rosenquist, R., Vassilakopoulos, T.P., Ott, G., Ogawa, S. and Damm, F.
Leukemia 37 (11): 2237-2249. November 2023

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Jahn, E., Saadati, M., Fenaux, P., Gobbi, M., Roboz, G.J., Bullinger, L., Lutsik, P., Riedel, A., Plass, C., Jahn, N., Walter, C., Holzmann, K., Hao, Y., Naim, S., Schreck, N., Krzykalla, J., Benner, A., Keer, H.N., Azab, M., Döhner, K. and Döhner, H.
Leukemia 37 (11): 2187-2196. November 2023

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.
Eifert, T., Hsu, C.J., Becker, A.L., Graessle, S., Horne, A., Bemmann, F., Zhang, Q., Heuser, M., Vasioukhin, V., Scholl, S., Hochhaus, A., Siegerist, F., Endlich, N., Bullinger, L., Lane, S.W., Haas, S., Schnoeder, T.M and Heidel, F.H.
Leukemia 37 (10): 2027-2035. October 2023

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
Straube, J., Eifert, T., Vu, T., Janardhanan, Y., Haldar, R., von Eyss, B., Cooper, L., Bruedigam, C., Ling, V.Y., Cooper, E., Patch, A.M., Bullinger, L., Schnoeder, T.M., Bywater, M., Heidel, F.H. and Lane, S.W.
Leukemia 37 (4): 741-750. April 2023

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri, L., Thorvaldsdottir, B., Sutton, L.A., Karakatsoulis, G., Meggendorfer, M., Parker, H., Nadeu, F., Brieghel, C., Laidou, S., Moia, R., Rossi, D., Catherwood, M., Kotaskova, J., Delgado, J., Rodríguez-Vicente, A.E., Benito, R., Rigolin, G.M., Bonfiglio, S., Scarfo, L., Mattsson, M., Davis, Z., Gogia, A., Rani, L., Baliakas, P., Foroughi-Asl, H., Jylhä, C., Skaftason, A., Rapado, I., Miras, F., Martinez-Lopez, J., de la Serna, J., Rivas, J.M.H., Thornton, P., Larráyoz, M.J., Calasanz, M.J., Fésüs, V., Mátrai, Z., Bödör, C., Smedby, K.E., Espinet, B., Puiggros, A., Gupta, R., Bullinger, L., Bosch, F., Tazón-Vega, B., Baran-Marszak, F., Oscier, D., Nguyen-Khac, F., Zenz, T., Terol, M.J., Cuneo, A., Hernández-Sánchez, M., Pospisilova, S., Mills, K., Gaidano, G., Niemann, C.U., Campo, E., Strefford, J.C., Ghia, P., Stamatopoulos, K. and Rosenquist, R.
Leukemia 37 (2): 339-347. February 2023

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Ling, V.Y., Straube, J., Godfrey, W., Haldar, R., Janardhanan, Y., Cooper, L., Bruedigam, C., Cooper, E., Tavakoli Shirazi, P., Jacquelin, S., Tey, S.K., Baell, J., Huang, F., Jin, J., Zhao, Y., Bullinger, L., Bywater, M.J. and Lane, S.W.
Leukemia 37 (1): 143-153. January 2023

2022

Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
Eichinger, A., Poetschger, U., Glogova, E., Bader, P., Basu, O., Beier, R., Burkhardt, B., Classen, C.F., Claviez, A., Corbacioglu, S., Deubzer, H.E., Greil, J., Gruhn, B., Güngör, T., Kafa, K., Kühl, J.S., Lang, P., Lange, B.S., Meisel, R., Müller, I., Sauer, M.G., Schlegel, P.G., Schulz, A., Stachel, D., Strahm, B., Wawer, A., Peters, C. and Albert, M.H.
Leukemia 36 (11): 2567-2576. November 2022

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn, N., Jahn, E., Saadati, M., Bullinger, L., Larson, R.A., Ottone, T., Amadori, S., Prior, T.W., Brandwein, J.M., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Ehninger, G., Heuser, M., Ganser, A., Pallaud, C., Gathmann, I., Krzykalla, J., Benner, A., Bloomfield, C.D., Thiede, C., Stone, R.M., Döhner, H. and Döhner, K.
Leukemia 36 (9): 2218-2227. September 2022

The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
Viñado, A.C., Calvo, I.A., Cenzano, I., Olaverri, D., Cocera, M., San Martin-Uriz, P., Romero, J.P., Vilas-Zornoza, A., Vera, L., Gomez-Cebrian, N., Puchades-Carrasco, L., Lisi-Vega, L.E., Apaolaza, I., Valera, P., Guruceaga, E., Granero-Molto, F., Ripalda-Cemborain, P., Luck, T.J., Bullinger, L., Planes, F.J., Rifon, J.J., Méndez-Ferrer, S., Yusuf, R.Z., Pardo-Saganta, A., Prosper, F. and Saez, B.
Leukemia 36 (8): 1969-1979. August 2022

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Fox, C.P., Schorb, E., Celico, C., Falautano, M., Nonis, A., La Rosée, P., Binder, M., Fabbri, A., Ilariucci, F., Krampera, M., Roth, Al., Hemmaway, C., Johnson, P.W., Linton, K.M., Pukrop, T., Gørløv, J.S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Zanni, M., Krause, S.W., Schmoll, H.J., Hertenstein, B., Rummel, M., Smith, J., Thurner, L., Cabras, G., Pennese, E., Ponzoni, M., Deckert, M., Politi, L.S., Finke, J., Ferranti, A., Cozens, K., Burger, E., Ielmini, N., Cavalli, F., Zucca, E. and Illerhaus, G.
Leukemia 36 (7): 1870-1878. July 2022

Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
Maschmeyer, G., Bullinger, L., Garcia-Vidal, C., Herbrecht, R., Maertens, J., Menna, P., Pagano, L., Thiebaut-Bertrand, A. and Calandra, T.
Leukemia 36 (5): 1215-1226. May 2022

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9.
Christen, F., Hablesreiter, R., Hoyer, K., Hennch, C., Maluck-Böttcher, A., Segler, A., Madadi, A., Frick, M., Bullinger, L., Briest, F. and Damm, F.
Leukemia 36 (4): 1102-1110. April 2022

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
Damaschin, C., Goergen, H., Kreissl, S., Plütschow, A., Breywisch, F., Mathas, S., Meissner, J., Sökler, M., Topp, M.S., Vucinic, V., Zimmermann, A., von Tresckow, B., Fuchs, M., Engert, A., Borchmann, P. and Eichenauer, D.A.
Leukemia 36 (2): 580-582. February 2022

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker, F.G., Du, L., Luck, T.J., Benner, A., Krzykalla, J., Gathmann, I., Voso, M.T., Amadori, S., Prior, T.W., Brandwein, J.M., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Savoie, L., Sierra, J., Pallaud, C., Sanz, M.A., Jansen, J.H., Niederwieser, D., Fischer, T., Ehninger, G., Heuser, M., Ganser, A., Bullinger, L., Larson, R.A., Bloomfield, C.D., Stone, R.M., Döhner, H., Thiede, C. and Döhner, K.
Leukemia 36 (1): 90-99. January 2022

2021

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
Lewis, R., Maurer, H.C., Singh, N., Gonzalez-Menendez, I., Wirth, M., Schick, M., Zhang, L., Isaakidis, K., Scherger, A.K., Schulze, V., Lu, J., Zenz, T., Steiger, K., Rad, R., Quintanilla-Martinez, L., Espeli, M., Balabanian, K., Keller, U. and Habringer, S.
Leukemia 35 : 2895-2905. October 2021

Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
Rapaport, F., Neelamraju, Y., Baslan, T., Hassane, D., Gruszczynska, A., de Massy, M.R., Farnoud, N., Haddox, S., Lee, T., Medina-Martinez, J., Sheridan, C., Thurmond, A., Becker, M., Bekiranov, S., Carroll, M., Moses Murdock, H., Valk, P.J.M., Bullinger, L., D’Andrea, R., Lowe, S.W., Neuberg, D., Levine, R.L., Melnick, A. and Garrett-Bakelman, F.E.
Leukemia 35 (9): 2688-2692. September 2021

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf, G.G., Altmann, B., Ziepert, M., D'Amore, F., Held, G., Greil, R., Tournilhac, O., Relander, T., Viardot, A., Wilhelm, M., Wilhelm, C., Pezzutto, A., Zijlstra, J.M., Van Den Neste, E., Lugtenburg, P.J., Doorduijn, J.K., van Gelder, M., van Imhoff, G.W., Zettl, F., Braulke, F., Nickelsen, M., Glass, B., Rosenwald, A., Gaulard, P., Loeffler, M., Pfreundschuh, M., Schmitz, N. and Trümper, L.
Leukemia 35 (1): 143-155. January 2021

2020

High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., Seifarth, W., Spieß, B., Wuchter, P., Krause, S., Kolb, H.J., Neubauer, A., Hossfeld, D.K., Nerl, C., Gratwohl, A., Baerlocher, G.M., Burchert, A., Brümmendorf, T.H., Hasford, J., Hochhaus, A., Saußele, S. and Baccarani, M.
Leukemia 34 (8): 2074-2086. August 2020

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part phase Ib/II study.
Rambaldi, A., Iurlo, A., Vannucchi, A.M., Noble, R., von Bubnoff, N., Guarini, A., Martino, B., Pezzutto, A., Carli, G., De Muro, M., Luciani, S., McMullin, M.F., Cambier, N., Marolleau, J.P., Mesa, R.A., Tibes, R., Pancrazzi, A., Gesullo, F., Bettica, P., Manzoni, S. and Di Tollo, S.
Leukemia 34 (8): 2234-2237. August 2020

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
Agrawal, M., Schwarz, P., Giaimo, B.D., Bedzhov, I., Corbacioglu, A., Weber, D., Gaidzik, V.I., Jahn, N., Rücker, F.G., Schroeder, T., Kindler, T., Wattad, M., Götze, K., Lübbert, M., Salwender, H., Ringhoffer, M., Lange, E., Koller, E., Thol, F., Heuser, M., Ganser, A., Bullinger, L., Paschka, P., Döhner, H., Geiger, H., Borggrefe, T., Döhner, K. and Oswald, F.
Leukemia 34 (2): 630-634. February 2020

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).
Meyer, T., Jahn, N., Lindner, S., Röhner, L., Dolnik, A., Weber, D., Scheffold, A., Köpff, S., Paschka, P., Gaidzik, V.I., Heckl, D., Wiese, S., Ebert, B.L., Döhner, H., Bullinger, L., Döhner, K. and Krönke, J.
Leukemia 34 (2): 404-415. February 2020

2019

getITD for FLT3-ITD-based MRD monitoring in AML.
Blätte, T.J., Schmalbrock, L.K., Skambraks, S., Lux, S., Cocciardi, S., Dolnik, A., Döhner, H., Döhner, K. and Bullinger, L.
Leukemia 33 (10): 2535-2539. October 2019

Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma.
Edginton-White, B., Cauchy, P., Assi, S.A., Hartmann, S., Riggs, A.G., Mathas, S., Cockerill, P.N. and Bonifer, C.
Leukemia 33 (6): 1463-1474. June 2019

Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies.
Çakmak-Görür, N., Radke, J., Rhein, S., Schumann, E., Willimsky, G., Heppner, F.L., Blankenstein, T. and Pezzutto, A.
Leukemia 33 (4): 1039-1043. April 2019

2018

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Döhner, H., Dolnik, A., Tang, L., Seymour, J.F., Minden, M.D., Stone, R.M., Del Castillo, T.B., Al-Ali, H.K., Santini, V., Vyas, P., Beach, C L., MacBeth, K.J., Skikne, B.S., Songer, S., Tu, N., Bullinger, L. and Dombret, H.
Leukemia 32 (12): 2546-2557. December 2018

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
L'Abbate, A., Tolomeo, D., Cifola, I., Severgnini, M., Turchiano, A., Augello, B., Squeo, G., D'Addabbo, P., Traversa, D., Daniele, G., Lonoce, A., Pafundi, M., Carella, M., Palumbo, O., Dolnik, A., Muehlematter, D., Schoumans, J., Van Roy, N., De Bellis, G., Martinelli, G., Merla, G., Bullinger, L., Haferlach, C. and Storlazzi, C.T.
Leukemia 32 (10): 2152-2166. October 2018

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
Rudat, S., Pfaus, A., Cheng, Y.Y., Holtmann, J., Ellegast, J.M., Bühler, C., Marcantonio, D.D., Martinez, E., Göllner, S., Wickenhauser, C., Müller-Tidow, C., Lutz, C., Bullinger, L., Milsom, M.D., Sykes, S.M., Fröhling, S. and Scholl, C.
Leukemia 32 (10): 2189-2202. October 2018

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.
Arends, C.M., Galan-Sousa, J., Hoyer, K., Chan, W., Jäger, M., Yoshida, K., Seemann, R., Noerenberg, D., Waldhueter, N., Fleischer-Notter, H., Christen, F., Schmitt, C.A., Dörken, B., Pelzer, U., Sinn, M., Zemojtel, T., Ogawa, S., Märdian, S., Schreiber, A., Kunitz, A., Krüger, U., Bullinger, L., Mylonas, E., Frick, M. and Damm, F.
Leukemia 32 (9): 1908-1919. September 2018

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
Schleussner, N., Merkel, O., Costanza, M., Liang, H.C., Hummel, F., Romagnani, C., Durek, P., Anagnostopoulos, I., Hummel, M., Jöhrens, K., Niedobitek, A., Griffin, P.R., Piva, R., Sczakiel, H.L., Woessmann, W., Damm-Welk, C., Hinze, C., Stoiber, D., Gillissen, B., Turner, S.D., Kaergel, E., von Hoff, L., Grau, M., Lenz, G., Dörken, B., Scheidereit, C., Kenner, L., Janz, M. and Mathas, S.
Leukemia 32 (9): 1994-2007. September 2018

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Paschka, P., Schlenk, R.F., Weber, D., Benner, A., Bullinger, L., Heuser, M., Gaidzik, V.I., Thol, F., Agrawal, M., Teleanu, V., Lübbert, M., Fiedler, W., Radsak, M., Krauter, J., Horst, H.A., Greil, R., Mayer, K., Kündgen, A., Martens, U., Heil, G., Salih, H.R., Hertenstein, B., Schwänen, C., Wulf, G., Lange, E., Pfreundschuh, M., Ringhoffer, M., Girschikofsky, M., Heinicke, T., Kraemer, D., Göhring, G., Ganser, A., Döhner, K. and Döhner, H.
Leukemia 32 (7): 1621-1630. July 2018

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.
Mohr, J., Dash, B.P., Schnoeder, T.M., Wolleschak, D., Herzog, C., Tubio Santamaria, N., Weinert, S., Godavarthy, S., Zanetti, C., Naumann, M., Hartleben, B., Huber, T.B., Krause, D.S., Kähne, T., Bullinger, L. and Heidel, F.H.
Leukemia 32 (5): 1211-1221. May 2018

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Gaidzik, V.I., Weber, D., Paschka, P., Kaumanns, A., Krieger, S., Corbacioglu, A., Krönke, J., Kapp-Schwoerer, S., Krämer, D., Horst, H.A., Schmidt-Wolf, I., Held, G., Kündgen, A., Ringhoffer, M., Götze, K., Kindler, T., Fiedler, W., Wattad, M., Schlenk, R.F., Bullinger, L., Teleanu, V., Schlegelberger, B., Thol, F., Heuser, M., Ganser, A., Döhner, H. and Döhner, K.
Leukemia 32 (1): 30-37. January 2018

2017

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H.J., Neubauer, A., Hossfeld, D.K., Nerl, C., Gratwohl, A., Baerlocher, G.M., Heim, D., Brümmendorf, T.H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M.C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M.C., Hänel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C.A., Lindemann, H.W., Waller, C.F., Pfreundschuh, M., Spiekermann, K., Berdel, W.E., Müller, L., Edinger, M., Mayer, J., Beelen, D.W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M.J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A. and Hasford, J.
Leukemia 31 (11): 2398-2406. November 2017

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel, V.N., Giaimo, B.D., Schwarz, P., Soller, K., Vas, V., Bartkuhn, M., Blätte, T.J., Döhner, K., Bullinger, L., Borggrefe, T., Geiger, H. and Oswald, F.
Leukemia 31 (11): 2491-2502. November 2017

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Young, E., Noerenberg, D., Mansouri, L., Ljungström, V., Frick, M., Sutton, L.A., Blakemore, S.J., Galan-Sousa, J., Plevova, K., Baliakas, P., Rossi, D., Clifford, R., Roos-Weil, D., Navrkalova, V., Dörken, B., Schmitt, C.A., Smedby, K.E., Juliusson, G., Giacopelli, B., Blachly, J.S., Belessi, C., Panagiotidis, P., Chiorazzi, N., Davi, F., Langerak, A.W., Oscier, D., Schuh, A., Gaidano, G., Ghia, P., Xu, W., Fan, L., Bernard, O.A., Nguyen-Khac, F., Rassenti, L., Li, J., Kipps, T.J., Stamatopoulos, K., Pospisilova, S., Zenz, T., Oakes, C.C., Strefford, J.C., Rosenquist, R. and Damm, F.
Leukemia 31 (7): 1547-1554. July 2017

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V., Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., Mügge, L.O., Straka, C., Engelhardt, M., Döhner, H., Einsele, H., Bassermann, F., Bargou, R., Knop, S. and Langer, C.
Leukemia 31 (6): 1363-1367. June 2017

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol, F., Klesse, S., Köhler, L., Gabdoulline, R., Kloos, A., Liebich, A., Wichmann, M., Chaturvedi, A., Fabisch, J., Gaidzik, V.I., Paschka, P., Bullinger, L., Bug, G., Serve, H., Göhring, G., Schlegelberger, B., Lübbert, M., Kirchner, H., Wattad, M., Kraemer, D., Hertenstein, B., Heil, G., Fiedler, W., Krauter, J., Schlenk, R.F., Döhner, K., Döhner, H., Ganser, A. and Heuser, M.
Leukemia 31 (6): 1286-1295. June 2017

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.
Jahn, N., Agrawal, M., Bullinger, L., Weber, D., Corbacioglu, A., Gaidzik, V.I., Schmalbrock, L., Thol, F., Heuser, M., Krauter, J., Göhring, G., Kündgen, A., Fiedler, W., Wattad, M., Held, G., Köhne, C.H., Horst, H.A., Lübbert, M., Ganser, A., Schlenk, R.F., Döhner, H., Döhner, K. and Paschka, P.
Leukemia 31 (4): 1012-1015. April 2017

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.
Wurster, K.D., Hummel, F., Richter, J., Giefing, M., Hartmann, S., Hansmann, M.L., Kreher, S., Köchert, K., Krappmann, D., Klapper, W., Hummel, M., Wenzel, S.S., Lenz, G., Janz, M., Dörken, B., Siebert, R. and Mathas, S.
Leukemia 31 (3): 602-613. March 2017

2016

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik, V.I., Teleanu, V., Papaemmanuil, E., Weber, D., Paschka, P., Hahn, J., Wallrabenstein, T., Kolbinger, B., Köhne, C.H., Horst, H.A., Brossart, P., Held, G., Kündgen, A., Ringhoffer, M., Götze, K., Rummel, M., Gerstung, M., Campbell, P., Kraus, J.M., Kestler, H.A., Thol, F., Heuser, M., Schlegelberger, B., Ganser, A., Bullinger, L., Schlenk, R.F., Döhner, K. and Döhner, H.
Leukemia 30 (11): 2160-2168. November 2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
Theis, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Weber, D., Bullinger, L., Heuser, M., Ganser, A., Thol, F., Schlegelberger, B., Göhring, G., Köhne, C.H., Germing, U., Brossart, P., Horst, H.A., Haase, D., Götze, K., Ringhoffer, M., Fiedler, W., Nachbaur, D., Kindler, T., Held, G., Lübbert, M., Wattad, M., Salih, H.R., Krauter, J., Döhner, H., Schlenk, R.F. and Döhner, K.
Leukemia 30 (11): 2248-2250. November 2016

GPR56 contributes to the development of acute myeloid leukemia in mice.
Daria, D., Kirsten, N., Muranyi, A., Mulaw, M., Ihme, S., Kechter, A., Hollnagel, M., Bullinger, L., Döhner, K., Döhner, H., Feuring-Buske, M. and Buske, C.
Leukemia 30 (8): 1734-1741. August 2016

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Arreba-Tutusaus, P., Mack, T.S., Bullinger, L., Schnöder, T.M., Polanetzki, A., Weinert, S., Ballaschk, A., Wang, Z., Deshpande, A.J., Armstrong, S.A., Döhner, K., Fischer, T. and Heidel, F.H.
Leukemia 30 (5): 1220-1225. May 2016

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial.
Ferrero, S., Pastore, A., Scholz, C.W., Forstpointner, R., Pezzutto, A., Bergmann, L., Truemper, L., Finke, J., Keller, U., Ghione, P., Passera, R., Hiddemann, W., Weigert, O., Unterhalt, M. and Dreyling, M.
Leukemia 30 (4): 984-987. April 2016

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
Nowek, K., Sun, S.M., Dijkstra, M.K., Bullinger, L., Döhner, H., Erkeland, S.J., Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (2): 303-9. February 2016

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
Nowek, K., Sun, S.M., Bullinger, L., Bindels, E.M.J., Exalto, C., Dijkstra, M.K., van Lom, K., Döhner, H., Erkeland, S.J., Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (1): 229-37. January 2016

2015

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey.
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S.K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F.S., Na, I.K., Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Lübbert, M., Wäsch, R., Scheid, C., Stölzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Gräff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G.U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B.R., Arnold, R., Kröger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N.
Leukemia 29 (10): 2062-2068. October 2015

Cellular origin of prognostic chromosomal aberrations in AML patients.
Mora-Jensen, H., Jendholm, J., Rapin, N., Andersen, M.K., Roug, A.S., Bagger, F.O., Bullinger, L., Winther, O., Borregaard, N., Porse, B.T. and Theilgaard-Mönch, K.
Leukemia 29 (8): 1785-9. August 2015

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., Staiger, A., Chai, A., Sandmann, T., Madle, H., Doerken, B., Chu, Y.W., Chen, A.I., Lebovic, D., Salles, G.A., Czuczman, M.S., Palanca-Wessels, M.C., Press, O.W., Advani, R., Morschhauser, F., Cheson, B.D., Lenz, P., Ott, G., Polson, A.G., Mundt, K.E. and Lenz, G.
Leukemia 29 (7): 1578-1586. July 2015

The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells.
Ullrich, K., Blumenthal-Barby, F., Lamprecht, B., Koechert, K., Lenze, D., Hummel, M., Mathas, S., Doerken, B. and Janz, M.
Leukemia 29 (5): 1213-1218. May 2015

TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer, A., Jakobsen, J.S., Ohlsson, E., Rapin, N., Waage, J., Billing, M., Bullinger, L., Karlsson, S. and Porse, B.T.
Leukemia 29 (5): 1018-1031. May 2015

2014

The leukemogenicity of Hoxa9 depends on alternative splicing.
Stadler, C R, Vegi, N, Mulaw, M A, Edmaier, K E, Rawat, V P S, Dolnik, A, Bullinger, L., Heilmeier, B, Quintanilla-Fend, L, Spiekermann, K, Hiddemann, W, Döhner, K, Döhner, H, Feuring-Buske, M and Buske, C
Leukemia 28 (9): 1838-1843. September 2014

Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.
Schneider, V., Zhang, L., Bullinger, L., Rojewski, M., Hofmann, S., Wiesneth, M., Schrezenmeier, H., Götz, M., Botzenhardt, U., Barth, T.F.E., Döhner, K., Döhner, H. and Greiner, J.
Leukemia 28 (8): 1759-62. August 2014

Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A.
Auer, F., Rueschendorf, F., Gombert, M., Husemann, P., Ginzel, S., Izraeli, S., Harit, M., Weintraub, M., Weinstein, O.Y., Lerer, I., Stepensky, P., Borkhardt, A. and Hauer, J.
Leukemia 28 (5): 1136-1138. May 2014

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
Dawson, M.A., Gudgin, E.J., Horton, S.J., Giotopoulos, G., Meduri, E., Robson, S., Cannizzaro, E., Osaki, H., Wiese, M., Putwain, S., Fong, C.Y., Grove, C., Craig, J., Dittmann, A., Lugo, D., Jeffrey, P., Drewes, G., Lee, K., Bullinger, L., Prinjha, R.K., Kouzarides, T., Vassiliou, G.S. and Huntly, B.J.P.
Leukemia 28 (2): 311-320. February 2014

2013

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Wenzel, S.S., Grau, M., Mavis, C., Hailfinger, S., Wolf, A., Madle, H., Deeb, G., Doerken, B., Thome, M., Lenz, P., Dirnhofer, S., Hernandez-Ilizaliturri, F.J., Tzankov, A. and Lenz, G.
Leukemia 27 (6): 1381-1390. June 2013

Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or Imatinib.
Kim, T.D., Rea, D., Schwarz, M., Grille, P., Nicolini, F.E., Rosti, G., Levato, L., Giles, F.J., Dombret, H., Mirault, T., Labussiere, H., Lindhorst, R., Haverkamp, W., Buschmann, I., Doerken, B. and le Coutre, P.D.
Leukemia 27 (6): 1316-1321. 5 April 2013

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
Krivtsov, A.V., Figueroa, M.E., Sinha, A.U., Stubbs, M.C., Feng, Z., Valk, P.J.M., Delwel, R., Döhner, K., Bullinger, L., Kung, A.L., Melnick, A.M. and Armstrong, S.A.
Leukemia 27 (4): 852-60. April 2013

The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.
Sun, S.M., Rockova, V., Bullinger, L., Dijkstra, M.K., Döhner, H., Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 27 (1): 100-6. January 2013

2012

Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.
Schwarzer, R., Doerken, B. and Jundt, F.
Leukemia 26 (4): 806-813. April 2012

NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia.
Terwey, T.H., Vega-Ruiz, A., Hemmati, P.G., Martus, P., Dietz, E., le Coutre, P., Massenkeil, G., Doerken, B. and Arnold, R.
Leukemia 26 (3): 536-542. March 2012

2008

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation.
Schwarzer, R., Kaiser, M., Acikgoez, O., Heider, U., Mathas, S., Preissner, R., Sezer, O., Doerken, B. and Jundt, F.
Leukemia 22 (12): 2273-2277. December 2008

Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma.
Jundt, F., Acikgoez, O., Kwon, S.H., Schwarzer, R., Anagnostopoulos, I., Wiesner, B., Mathas, S., Hummel, M., Stein, H., Reichardt, H.M. and Doerken, B.
Leukemia 22 (8): 1587-1594. August 2008

2007

Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells.
Janz, M., Stuehmer, T., Vassilev, L.T. and Bargou, R.C.
Leukemia 21 (4): 772-779. April 2007

2006

High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis.
Steiner, K., Graf, M., Hecht, K., Reif, S., Rossbacher, L., Pfister, K., Kolb, H.J., Schmetzer, H.M. and Multhoff, G.
Leukemia 20 (11): 2076-2079. November 2006

Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Einsiedel, H.G., Kawan, L., Eckert, C., Witt, O., Fichtner, I., Henze, G. and Seeger, K.
Leukemia 20 (8): 1435-1436. August 2006

2005

Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
Schmelz, K., Sattler, N., Wagner, M., Luebbert, M., Doerken, B. and Tamm, I.
Leukemia 19 : 103-111. 1 January 2005

2004

Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient.
Subklewe, M., Nagy, M., Schoch, C., Jenisch, S., Siebert, R., Gesk, S., Neuhaus, P., Doerken, B. and Schmidt, C.A.
Leukemia 18 (12): 2050-2053. 7 October 2004

A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells.
Hoenemann, D., Kufer, P., Rimpler, M.M., Chatterjee, M., Friedl, S., Riecher, F., Bommert, K., Doerken, B. and Bargou, R.C.
Leukemia 18 (3): 636-644. 1 January 2004

PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.
Lentzsch, S., Chatterjee, M., Gries, M., Bommert, K., Gollasch, H., Doerken, B. and Bargou, R.C.
Leukemia 18 (11): 1883-1890. 1 January 2004

2003

Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk, R.F., Benner, A., Hartmann, F., del Valle, F., Weber, C., Pralle, H., Fischer, J.T., Gunzer, U., Pezzutto, A., Weber, W., Grimminger, W., Preiss, J., Hensel, M., Froehling, S., Doehner, K., Haas, R. and Doehner, H.
Leukemia 17 (8): 1521-1528. 1 August 2003

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Loeffler, A., Gruen, M., Wuchter, C., Schriever, F., Kufer, P., Dreier, T., Hanakam, F., Baeuerle, P.A., Bommert, K., Karawajew, L., Doerken, B. and Bargou, R.C.
Leukemia 17 (5): 900-909. May 2003

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Lentzsch, S., LeBlanc, R., Podar, K., Davies, F., Lin, B., Hideshima, T., Catley, L., Stirling, D.I. and Anderson, K.C.
Leukemia 17 : 41-44. 1 January 2003

2002

Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy.
Kern, W., Haferlach, T., Schnittger, S., Ludwig, W.D., Hiddemann, W. and Schoch, C.
Leukemia 16, 10 : 2084-2091. 1 October 2002

Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases.
Borkhardt, A., Wuchter, C., Viehmann, S., Pils, S., Teigler-Schlegel, A., Stanulla, M., Zimmermann, M., Ludwig, W.D., Janka-Schaub, G., Schrappe, M. and Harbott, J.
Leukemia 16, 9 : 1685-1690. 1 September 2002

Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Bosanquet, A.G., Sturm, I., Wieder, T., Essmann, F., Bosanquet, M.I., Head, F.J., Doerken, B. and Daniel, P.T.
Leukemia 16 (6): 1035-1044. June 2002

2001

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Gupta, D., Treon, S.P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.T., Lin, B., Lentzsch, S., Davies, F.E., Chauhan, D., Schlossman, R.L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D.I. and Anderson, K.C.
Leukemia 15 : 1950-1961. 1 December 2001

Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts.
Wieder, T., Prokop, A., Bagci, B., Essmann, F., Bernicke, D., Schulze-Osthoff, K., Doerken, B., Schmalz, H.G., Daniel, P.T. and Henze, G.
Leukemia 15 (11): 1735-1742. 1 November 2001

The kiss of death: promises and failures of death receptors and ligands in cancer therapy.
Daniel, P.T., Wieder, T., Sturm, I. and Schulze-Osthoff, K.
Leukemia 15 (7): 1022-1032. 1 July 2001

Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation.
Cai, Z., Lin, M., Wuchter, C., Ruppert, V., Doerken, B., Ludwig, W.D. and Karawajew, L.
Leukemia 15 : 567-574. 1 January 2001

In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappaB activity.
Wuchter, C., Krappmann, D., Cai, Z., Ruppert, V., Scheidereit, C., Doerken, B., Ludwig, W.D. and Karawajew, L.
Leukemia 15 (6): 921-928. 1 January 2001

2000

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster.
Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.D., Henze, G., Gadner, H., Odenwald, E. and Riehm, H.
Leukemia 14 (12): 2205-2222. 1 December 2000

Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo.
Prokop, A., Wieder, T., Sturm, I., Essmann, F., Seeger, K., Wuchter, C., Ludwig, W.D., Henze, G., Doerken, B. and Daniel, P.T.
Leukemia 14 : 1606-1613. 1 September 2000

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.
Lengfelder, E., Reichert, A., Schoch, C., Haase, D., Haferlach, T., Loeffler, H., Staib, P., Heyll, A., Seifarth, W., Saussele, S., Fonatsch, C., Gassmann, W., Ludwig, W.D., Hochhaus, A., Beelen, D., Aul, C., Sauerland, M.C., Heinecke, A., Hehlmann, R., Woermann, B., Hiddemann, W. and Buechner, T.
Leukemia 14 : 1362-1370. 1 August 2000

Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1.
Wuchter, C., Harbott, J., Schoch, C., Schnittger, S., Borkhardt, A., Karawajew, L., Ratei, R., Ruppert, V., Haferlach, T., Creutzig, U., Doerken, B. and Ludwig, W.D.
Leukemia 14 : 1232-1238. 1 July 2000

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.
Kordes, U., Krappmann, D., Heissmeyer, V., Ludwig, W.D. and Scheidereit, C.
Leukemia 14 (3): 399-402. March 2000

Granulocyte colony-stimulating factor receptor expression and 11q23/MLL genotype in childhood acute lymphoblastic leukemia developing during the first 18 months of life.
Stanulla, M., Kasper, B., Schrappe, M., Viehmann, S., Harbott, J., Ludwig, W.D. and Welte, K.
Leukemia 14 : 337-338. 1 February 2000

Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients.
Bohlander, S.K., Muschinsky, V., Schrader, K., Siebert, R., Schlegelberger, B., Harder, L., Schemmel, V., Fonatsch, C., Ludwig, W.D., Hiddemann, W. and Dreyling, M.H.
Leukemia 14 : 93-99. 1 January 2000

1999

Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Wuchter, C., Karawajew, L., Ruppert, V., Buechner, T., Schoch, C., Hafelach, T., Ratei, R., Doerken, B. and Ludwig, W.D.
Leukemia 13 : 1943-1953. 1 December 1999

First non-imported HTLV-1 positive adult T cell leukemia/lymphoma (ATLL) in Germany.
Reinhardt, P., Maschmeyer, G., Schulze, G., Fleischer, C., Ellerbrok, H., Schlegelberger, B., Stein, H., Pauli, G. and Ludwig, W.D.
Leukemia 13 : 1296-1297. 1 August 1999

Immunophenotypic and immunogenotypic characteristics of TCR gammadelta+ T cell acute lymphoblastic leukemia.
Langerak, A.W., Wolvers-Tettero, I.L., van den Beemd, M.W.M., van Wering, E.R., Ludwig, W.D., Haehlen, K., Necker, A. and van Dongen, J.J.M.
Leukemia 13 : 206-214. 1 February 1999

1998

High rate of chromosome abnormalities detected by fluorescence in situ hybridization using BCR and ABL probes in adult acute lymphoblastic leukemia.
Rieder, H., Bonwetsch, C., Janssen, L.A.J., Maurer, J., Janssen, J.W.G., Schwartz, S., Ludwig, W.D., Gassmann, W., Bartram, C.R., Thiel, E., Loeffler, H., Gokbuget, N., Hoelzer, D. and Fonatsch, C.
Leukemia 12 : 1473-1481. 1 September 1998

Expression and regulation of c-kit receptor and response to stem cell factor in childhood malignant T-lymphoblastic cells.
Tomeczkowski, J., Frick, D., Schwinzer, B., Wittner, N., Ludwig, W.D., Reiter, A., Welte, K. and Sykora, K.W.
Leukemia 12 : 1221-1229. 1 August 1998

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern, W., Aul, C., Maschmeyer, G., Schoenrock-Nabulsi, R., Ludwig, W.D., Bartholomaeus, A., Bettelheim, P., Woermann, B., Buechner, T. and Hiddemann, W.
Leukemia 12 : 1049-1055. 1 July 1998

Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials.
Dordelmann, M., Schrappe, M., Reiter, A., Zimmermann, M., Graf, N., Schott, G., Lampert, F., Harbott, J., Niemeyer, C., Ritter, J., Dorffel, W., Nessler, G., Kuhl, J. and Riehm, H.
Leukemia 12 : 645-651. 1 May 1998

Detection of hyperdiploid karyotypes (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH).
Ritterbach, J., Hiddemann, W., Beck, J.D., Schrappe, M., Janka-Schaub, G., Ludwig, W.D., Harbott, J. and Lampert, F.
Leukemia 12 : 427-433. 1 March 1998

1997

Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells.
Karawajew, L., Wuchter, C., Ruppert, V., Drexler, H., Gruss, H.J., Doerken, B. and Ludwig, W.D.
Leukemia 11 : 1245-1252. 1 January 1997

1996

Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.
Creutzig, U., Ritter, J., Vormoor, J., Ludwig, W.D., Niemeyer, C., Reinisch, I., Stollmann-Gibbels, B., Zimmermann, M. and Harbott, J.
Leukemia 10 (11): 1677-1686. 1 November 1996

Classification of acute leukemias: reply from EGIL to Dr van Dongen.
Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. and van't Veer, M.B.
Leukemia 10 : 1363-1364. 1 January 1996

Effects of FLT3 ligand on human leukemia cells. I. proliferative response of myeloid leukemia cells.
Dehmel, U., Zaborski, M., Meierhoff, G., Rosnet, O., Birnbaum, D., Ludwig, W.D., Quentmeier, H. and Drexler, H.G.
Leukemia 10 (2): 261-270. 1 January 1996

Expression of the receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia cells.
Quentmeier, H., Zaborski, M., Graf, G., Ludwig, W.D. and Drexler, H.G.
Leukemia 10 : 297-310. 1 January 1996

Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies.
Rothe, G., Schmitz, G., Adorf, D., Barlage, S., Gramatzki, M., Hanenberg, H., Hoeffkes, H.G., Janossy, G., Knuechel, R., Ludwig, W.D., Nebe, T., Nerl, C., Orfao, A., Serke, S., Sonnen, R., Tichelli, A. and Woermann, B.
Leukemia 10 (5): 877-895. 1 January 1996

Incidence and clinical outcome of children with bcr/abl positive acute lymphoblastic leukemia (ALL): a prospective rt PCR study based on 673 patients enrolled in the German Pediatric Multicenter therapy trials ALL BFM 90 and coALL 05 92.
Schlieben, S., Borkhardt, A., Reinisch, I., Ritterbach, J., Janssen, J.W., Ratei, R., Schrappe, M., Repp, R., Zimmermann, M., Kabisch, H., Janka-Schaub, G., Bartram, C.R., Ludwig, W.D., Riehm, H., Lampert, F. and Harbott, J.
Leukemia 10 : 957-963. 1 January 1996

1995

Proposals for the immunological classification of acute leukemias.
Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. and Vantveer, M.B.
Leukemia 9 (10): 1783-1786. 1 October 1995

Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia.
Meckenstock, G., Heyll, A., Schneider, E.M., Hildebrandt, B., Runde, V., Aul, C., Bartram, C.R., Ludwig, W.D. and Schneider, W.
Leukemia 9 : 260-264. 1 January 1995

1994

Mechanisms of p53 alteration in acute leukemias.
Schottelius, A., Brennscheidt, U., Ludwig, W.D., Mertelsmann, R.H., Herrmann, F. and Lubbert, M.
Leukemia 8 : 1673-1681. 1 October 1994

Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).
Fonatsch, C., Gudat, H., Lengfelder, E., Wandt, H., Silling-Engelhardt, G., Ludwig, W.D., Thiel, E., Freund, M., Bodenstein, H., Schwieder, G., Gruenelsen, A., Aul, C., Schnittger, S., Rieder, H., Haase, D. and Hild, F.
Leukemia 8 (8): 1318-1326. 1 August 1994

Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia cells.
Baker, S.J., Pawlita, M., Leutz, A. and Hoelzer, D.
Leukemia 8 (8): 1309-1317. August 1994

Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11).
Griesinger, F., Elfers, H., Ludwig, W.D., Falk, M., Rieder, H., Harbott, J., Lampert, F., Heinze, B., Hoelzer, D., Thiel, E., Riehm, H., Woermann, B., Fonatsch, C. and Hiddemann, W.
Leukemia 8 : 542-548. 1 January 1994

APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice.
Luecking-Famira, K.M., Daniel, P.T., Moeller, P., Krammer, P.H. and Debatin, K.M.
Leukemia 8 : 1825-1833. 1 January 1994

Ras point mutations occur in acute myeloid leukemia with illegitimate T-cell receptor delta gene rearrangement.
Schmidt, C.A., Przybylski, G., Vogel, D., Ludwig, W.D., Oettle, H., Neubauer, A. and Siegert, W.
Leukemia 8 : 102-105. 1 January 1994

Characterization of the monocyte-specific esterase (MSE) gene.
Uphoff, C.C., Hu, Z.B., Gignac, S.M., Ma, W., Rainey, F.A., Kreutz, M., Ludwig, W.D. and Drexler, H.G.
Leukemia 8 : 1510-1526. 1 January 1994

t(5;14)(q33-34;q11), a new recurring cytogenetic abnormality in childhood acute leukemia.
Whitlock, J.A., Raimondi, S.C., Harbott, J., Morris, S.W., McCurley, T.L., Hansen-Hagge, T.E., Ludwig, W.D., Weimann, G. and Bartram, C.R.
Leukemia 8 : 1539-1543. 1 January 1994

Timing of peripheral blood progenitor cell (PBPC) collections during recovery from chemotherapy supported by haematopoietic growth factor.
van Hoef, M.E., Baumann, I., Lange, C., De Wynter, E.A., Testa, N.G. and Howell, A.
Leukemia 8 : 2020-2021. 1 January 1994

1993

Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance.
Drexler, H.G., Thiel, E. and Ludwig, W.D.
Leukemia 7 (4): 489-498. 1 April 1993

tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.
Breit, T.M., Beishuizen, A., Ludwig, W.D., Mol, E.J., Adriaansen, H.J., van Wering, E.R. and van Dongen, J.J.
Leukemia 7 : 2004-2011. 1 January 1993

Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia.
Drexler, H.G., Sperling, C. and Ludwig, W.D.
Leukemia 7 : 1142-1150. 1 January 1993

Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84).
Hoelzer, D., Thiel, E., Ludwig, W.D., Loeffler, H., Buechner, T., Freund, M., Heil, G., Hiddemann, W., Maschmeyer, G., Voelkers, B., Goekbuget, N. and Aydemir, U.
Leukemia 7 Suppl. 2 : S130-S134. 1 January 1993

Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses.
Izraeli, S., Janssen, J.W., Haas, O.A., Harbott, J., Brok Simoni, F., Walther, J.U., Kovar, H., Henn, T., Ludwig, W.D., Reiter, A., Rechavi, G., Bartram, C.R., Gadner, H. and Lion, T.
Leukemia 7 : 671-678. 1 January 1993

Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia.
Izraeli, S., Henn, T., Strobl, H., Ludwig, W.D., Kovar, H., Haas, O.A., Harbott, J., Bartram, C.R., Gadner, H. and Lion, T.
Leukemia 7 : 2054-2056. 1 January 1993

SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia.
Janssen, J.W., Ludwig, W.D., Sterry, W. and Bartram, C.R.
Leukemia 7 : 1204-1210. 1 January 1993

Translocation t(1;22) mimicking t(1;19) in a child with acute lymphoblastic leukemia as revealed by chromosome painting.
Rieder, H., Kolbus, U., Koop, U., Ludwig, W.D., Stollmann-Gibbels, B. and Fonatsch, C.
Leukemia 7 : 1663-1666. 1 January 1993

1992

Combined effect of very early intensification and prolonged post- remission chemotherapy in patients with AML.
Buechner, T., Hiddemann, W., Schaefer, U.W., Loeffler, H., Maschmeyer, G., Ludwig, W.D., Aul, C., Lathan, B. and Heinecke, A.
Leukemia 6 Suppl. 4 : 68-70. 1 January 1992

Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.
Buechner, T., Hiddemann, W., Woermann, B., Loeffler, H., Maschmeyer, G., Hossfeld, D., Ludwig, W.D., Nowrousian, M., Aul, C. and Schaefer, U.W.
Leukemia 6 Suppl 2 : 68-71. 1 January 1992

The German multicentre trials for treatment of acute lymphoblastic leukemia in adults. The German Adult ALL Study Group.
Hoelzer, D., Thiel, E., Ludwig, W.D., Loeffler, H., Buechner, T., Freund, M., Heil, G., Hiddemann, W., Maschmeyer, G., Voelkers, B. and Aydemir, U.
Leukemia 6 (Suppl. 2): 175-177. 1992